Prazosin for Nightmares
Prazosin can be used for nightmares, particularly those associated with PTSD, though recent evidence has led to a downgraded recommendation due to mixed efficacy results, especially in patients on concurrent antidepressants. 1
Current Guideline Position
The American Academy of Sleep Medicine (2018) acknowledges that prazosin remains the first-choice pharmacologic therapy for nightmare disorder despite contradictory evidence, recognizing that many patients respond very well clinically. 1 However, the recommendation was downgraded after a large 304-patient VA study showed no significant benefit over placebo at 26 weeks, with 78% of participants on concurrent antidepressants. 1
Evidence for Efficacy
Supporting Evidence
Multiple smaller RCTs demonstrated significant benefit:
Vietnam veterans: Nightmare scores decreased from 6.9 to 3.6 with prazosin versus 7.1 to 6.7 with placebo (mean dose 9.5 mg/day). 1
Civilian PTSD patients: An 8-week trial in 100 trauma victims showed nightmare frequency decreased from 2.42 to 0.85 with prazosin versus 2.48 to 2.30 with placebo. 1
Active-duty soldiers: A 15-week trial showed 64% marked/moderate improvement with prazosin versus 27% with placebo (p<0.001), using doses of 15.6 mg for men and 7.0 mg for women. 1
Meta-analysis (2021): Pooled data from 429 patients showed prazosin significantly improved overall PTSD scores (SMD = -0.31), nightmares (SMD = -0.75), and sleep quality (SMD = -0.57). 2
Contradictory Evidence
The largest trial (304 patients, 26 weeks) found no significant difference between prazosin and placebo on any outcome measure, with mean doses of 14.8 mg/day. 1 This negative result appears driven by an unusually large placebo effect and high rates of concurrent antidepressant use (78%). 2
Critical Medication Interaction
Concurrent SSRI use significantly reduces prazosin efficacy. 1 In the 2013 active-duty soldier trial, total PTSD symptoms decreased by 30.1 points in patients not on SSRIs versus only 9.6 points in those taking SSRIs. 1 This interaction may explain the negative results in the large VA study where most patients were on antidepressants. 1
Dosing Strategy
Start low and titrate slowly to minimize orthostatic hypotension and dizziness:
- Initial dose: 1 mg at bedtime 1
- Effective dose range: 1-20 mg, with typical doses of 8-15 mg 1
- Gender-specific dosing: Men typically require 15.6 mg; women 7.0 mg 1
- Titrate based on nightmare response over several weeks 1
Safety Profile
Prazosin is generally well-tolerated:
- Most common side effect: Transient dizziness and mild orthostatic hypotension, which typically resolve during treatment 1
- No falls or syncopal episodes reported in major trials 1
- No significant blood pressure changes in most studies 1
- Rare but serious: Priapism with rapid titration (avoid rapid dose escalation) 3
Clinical Algorithm
For PTSD-related nightmares:
- First-line: Consider prazosin if patient is NOT on SSRIs or willing to optimize/discontinue antidepressants 1
- Adjunctive therapy: Prazosin works best alongside psychotherapy; 91% of best responders were receiving concurrent psychotherapy 4
- Monitoring: Assess nightmare frequency weekly and blood pressure at each dose increase 1
- Duration: Benefits may take 8-15 weeks to fully manifest 1
- Discontinuation: Nightmares typically return to baseline when prazosin is stopped 1
Important Caveats
- Not FDA-approved for nightmares: Prazosin is only FDA-approved for hypertension 5
- Benzodiazepine interaction: Emerging evidence suggests concurrent benzodiazepine use may enhance prazosin efficacy for insomnia and PTSD severity, though this requires confirmation 6
- Limited non-PTSD data: Evidence primarily supports use in PTSD-related nightmares; one case report describes benefit in cancer-related nightmares 7
- Avoid in suicidal patients with nighttime-only dosing: One trial paradoxically showed worsening nighttime symptoms with bedtime-only prazosin in suicidal PTSD patients 8
Bottom Line
Prazosin remains a reasonable first-line pharmacologic option for PTSD-related nightmares, particularly in patients not taking SSRIs and receiving concurrent psychotherapy. 1 Start with 1 mg at bedtime and titrate slowly to 10-15 mg based on response and tolerability, monitoring for orthostatic symptoms. 1